NL-OMON29026尚未招募不适用
Eculizumab in patients with classic PNH: A cost effectivity study.
Radboud University Nijmegen Medical Centre (RUNMC)0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 25
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. PNH patients treated with eculizumab;
- •2. Aged >= 18 years;
排除标准
- •No informed consent.
研究者
相似试验
进行中（未招募）
3 期
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsParoxysmal Nocturnal HemoglobinuriaNCT04432584Hoffmann-La Roche190
已完成
3 期
Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaParoxysmal Hemoglobinuria, NocturnalNCT00130000National Heart, Lung, and Blood Institute (NHLBI)87
已完成
3 期
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With EculizumabHemoglobinuria, ParoxysmalNCT00122304Alexion Pharmaceuticals, Inc.85
进行中（未招募）
1 期
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study - SHEPHERDEUCTR2004-002795-42-IEALEXION PHARMACEUTICALS INCORPORATED97
进行中（未招募）
1 期
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study - SHEPHERDparoxysmal nocturnal hemoglobinuriaMedDRA version: 7.0Level: PTClassification code 10034042EUCTR2004-002795-42-ESALEXION PHARMACEUTICALS INCORPORATED97